Indefinite Delivery Contract SPE2DR25D9303

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain has issued a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts. The purpose is to establish multiple prime vendor contracts to provide worldwide pharmaceutical support, including brand, generic, and specialty drugs, as well as pharmaceutical-related products, to the Department of Defense (DoD), United States Coast Guard, and other designated government agencies and providers. This will be an unrestricted, fully competitive procurement with a firm-fixed price, requirements-type contract structure. The base period is 30 months with three 30-month option periods, for a total estimated value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. The contract is expected to be awarded in March 2024, with a 45-day solicitation period. DMS Pharmaceutical Group Inc., a woman-owned small business, currently holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support military healthcare facilities worldwide.